More specifically, inhibiting KIAA1429 expression could reduce the m6A modification of RAB27B mRNA, which is then recognized by YTHDF1, resulting in reduced stability of the mRNA, decreased expression of RAB27B, and consequently reduced proliferation and drug resistance of CML cells. The gene discussed is VIRMA; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.